Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ASP Isotopes (ASPI) Securities Fraud: Contact Berger Montague To Discuss Your Rights

ASPI

Philadelphia, Pennsylvania--(Newsfile Corp. - December 11, 2024) - A securities class action lawsuit has been filed against ASP Isotopes Inc. ("ASP Isotopes" or the "Company") (NASDAQ: ASPI). The lawsuit has been filed on behalf of purchasers of ASP Isotopes securities between October 30, 2024 and November 26, 2024, inclusive (the "Class Period").

CLICK HERE TO LEARN MORE ABOUT THIS LAWSUIT.

Investors who purchased or acquired ASP ISOTOPES securities during the Class Period may, no later than FEBRUARY 3, 2025, seek to be appointed as a lead plaintiff representative of the class.

Headquartered in Washington, DC, ASP Isotopes is a development-stage advanced materials company focused on the production, enrichment, and sale of isotopes. The Company purports to have multiple isotope enrichment plants currently under development in South Africa.

According to the lawsuit, ASP Isotopes and its senior executives failed to disclose to investors that the Company: (1) overstated the potential effectiveness of its enrichment technology; (2) overstated the development potential of its high-assay low-enriched uranium (HALEU) facility; and (3) overstated the Company's nuclear fuels operating segment results.

For additional information or to learn how to participate in this litigation, please contact Berger Montague: Andrew Abramowitz at aabramowitz@bm.net or (215) 875-3015, or Peter Hamner at phamner@bm.net or (215) 875-3048, or CLICK HERE.

A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the Court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Contact:

Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bm.net

Peter Hamner
Berger Montague PC
phamner@bm.net

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/233413



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today